In addition, it is likely influenced by the inherent heterogeneity and limited sample sizes of these studies, along with variations in patient groups, scoring methodologies (immunohistochemistry (IHQ) and mRNA), and in different samples (stroma and tumor, nucleated cell, or proportion of CD8/CD3) [26,27]. This evidence concerns the gene CD8A and neoplasm.